Circadian Regulator CLOCK Recruits Immune-Suppressive Microglia into the GBM Tumor Microenvironment
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Glioblastoma (GBM) is a lethal brain tumor containing a subpopulation of glioma stem cells (GSC). Pan-cancer analyses have revealed that stemness of cancer cells correlates positively with immunosuppressive pathways in many solid tumors, including GBM, prompting us to conduct a gain-of-function screen of epigenetic regulators that may influence GSC self-renewal and tumor immunity. The circadian regulator CLOCK emerged as a top hit in enhancing stem-cell self-renewal, which was amplified in about 5% of human GBM cases. CLOCK and its heterodimeric partner BMAL1 enhanced GSC self-renewal and triggered protumor immunity via transcriptional upregulation of OLFML3, a novel chemokine recruiting immune-suppressive microglia into the tumor microenvironment. In GBM models, CLOCK or OLFML3 depletion reduced intratumoral microglia density and extended overall survival. We conclude that the CLOCK–BMAL1 complex contributes to key GBM hallmarks of GSC maintenance and immunosuppression and, together with its downstream target OLFML3, represents new therapeutic targets for this disease. Significance: Circadian regulator CLOCK drives GSC self-renewal and metabolism and promotes microglia infiltration through direct regulation of a novel microglia-attracting chemokine, OLFML3. CLOCK and/or OLFML3 may represent novel therapeutic targets for GBM. This article is highlighted in the In This Issue feature, p. 327
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
Microenvironmental regulation of tumor progression and metastasis
Quail, D. F., & Joyce, J. A. (2013) · Nature Medicine · doi:10.1038/nm.3394 · Cited by 7,994 · cited 1×
“A hallmark feature of the GBM TME is an abundance of infiltrating immune cells (38) wherein microglia are known to contribute to an immunosuppressive microenvironment and support GBM progression (39).”
BackgroundComprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
The Somatic Genomic Landscape of Glioblastoma
Brennan, C. W., Verhaak, R. G. W., McKenna, A., Campos, B., Noushmehr, H., Salama, S. R., Zheng, S., Chakravarty, D., Sanborn, J. Z., Berman, S. H., et al. (2013) · Cell · doi:10.1016/j.cell.2013.09.034 · Cited by 5,016
Self-citationCSF-1R inhibition alters macrophage polarization and blocks glioma progression
Pyonteck, S. M., Akkari, L., Schuhmacher, A. J., Bowman, R. L., Sevenich, L., Quail, D. F., Olson, O. C., Quick, M. L., Huse, J. T., Teijeiro, V., et al. (2013) · Nature Medicine · doi:10.1038/nm.3337 · Cited by 2,463 · cited 1×
“To date, however, CSF1R inhibitor BLZ945 treatment of mouse GBM models have failed to deplete TAMs and elicited transient anti-tumor responses (47,48).”
BackgroundThe role of microglia and macrophages in glioma maintenance and progression
Hambardzumyan, D., Gutmann, D. H., & Kettenmann, H. (2016) · Nature Neuroscience · doi:10.1038/nn.4185 · Cited by 1,683 · cited 1×
“34), is strongly biased toward the M2 phenotype in both mouse and human GBM tumors (Supplementary Fig.”
BackgroundCircadian control of the immune system
Scheiermann, C., Kunisaki, Y., & Frenette, P. S. (2013) · Nature Reviews Immunology · doi:10.1038/nri3386 · Cited by 1,135 · cited 1×
“Here, our findings of CLOCK-regulated microglia recruitment are consistent with previous observations that the immune system can be regulated by circadian components (40) and that dysregulation of the intrinsic circadian clock can alter inflammatory responses (41, 42).”
BackgroundMolecular components of the mammalian circadian clock
Buhr, E. D., & Takahashi, J. S. (2013) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-25950-0_1 · Cited by 738 · cited 3×
“This complex can activate the expression of the PER and CRY genes, which ultimately forms a negative feedback loop to inhibit the activity of the CLOCK–BMAL1 complex (22).”
BackgroundInfluentialKRAS-IRF2 axis drives immune suppression and immune therapy resistance in colorectal cancer
Liao, W., Overman, M. J., Boutin, A. T., Shang, X., Zhao, D., Dey, P., Li, J., Wang, G., Lan, Z., Li, J., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.02.008 · Cited by 617 · cited 19×
“Genes & development 2019;33(11-12):591-609 doi 10.”
BackgroundInfluentialSelf-citationCore circadian clock genes regulate leukemia stem cells in AML
Puram, R. V., Kowalczyk, M. S., de Boer, C. G., Schneider, R. K., Miller, P. G., McConkey, M., Tothova, Z., Tejero, H., Heckl, D., Järås, M., et al. (2016) · Cell · doi:10.1016/j.cell.2016.03.015 · Cited by 274
Cited by
Macrophages and microglia in glioblastoma: heterogeneity, plasticity, and therapy
Khan, F., Pang, L., Dunterman, M., Lesniak, M. S., Heimberger, A. B., & Chen, P. (2023) · Journal of Clinical Investigation · doi:10.1172/jci163446 · Cited by 414
Self-citationLin, H., Liu, C., Hu, A., Zhang, D., Yang, H., & Mao, Y. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01544-7 · Cited by 392
Immunotherapy for glioblastoma: current state, challenges, and future perspectives
Liu, Y., Zhou, F., Ali, H., Lathia, J. D., & Chen, P. (2024) · Cellular & Molecular Immunology · doi:10.1038/s41423-024-01226-x · Cited by 336
Self-citationLoh, J.-J., & Ma, S. (2024) · Cell Stem Cell · doi:10.1016/j.stem.2024.04.004 · Cited by 314
Cancer and stress: NextGen strategies
Cui, B., Peng, F., Lu, J., He, B., Su, Q., Luo, H., Deng, Z., Jiang, T., Su, K., Huang, Y., et al. (2021) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2020.11.005 · Cited by 152
Mechanism and therapeutic potential of tumor-immune symbiosis in glioblastoma
Pang, L., Khan, F., Heimberger, A. B., & Chen, P. (2022) · Trends in Cancer · doi:10.1016/j.trecan.2022.04.010 · Cited by 67
Self-citationPharmacological targeting of the tumor–immune symbiosis in glioblastoma
Pang, L., Khan, F., Dunterman, M., & Chen, P. (2022) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2022.04.002 · Cited by 36
“For example, the circadian loco-motor output cycles kaput (CLOCK)-BMAL1 complex can upregulate olfactomedin-like 3 (OLFML3) transcription in GSCs, which, in turn, induces microglial in fi ltration into the GBM TME [29].”
BackgroundMethodSelf-citationCellular senescence in tumor immune escape: Mechanisms, implications, and therapeutic potential
You, L., & Wu, Q. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104628 · Cited by 21
Metadata
- Authors
- Chen, P., Hsu, W.-H., Chang, A., Tan, Z., Lan, Z., Zhou, A., Spring, D. J., Lang, F. F., Wang, Y. A., & DePinho, R. A.
- Venue
- Cancer Discovery
- Published
- 2020-03-01
- Volume
- 10
- Issue
- 3
- Pages
- 371-381
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W2999304067
- Cited by
- 215
- References
- 12
- FWCI
- 12.35
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.